Dyadic International Inc. (NASDAQ:DYAI) Sees Significant Decrease in Short Interest

Dyadic International Inc. (NASDAQ:DYAI) was the target of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 52,977 shares, a drop of 36.6% from the July 15th total of 83,534 shares. Based on an average trading volume of 212,919 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the shares of the stock are short sold.

Dyadic International Trading Down 0.9%

NASDAQ:DYAI traded down $0.01 during trading hours on Tuesday, hitting $0.77. The company had a trading volume of 129,166 shares, compared to its average volume of 182,936. Dyadic International has a 52 week low of $0.65 and a 52 week high of $1.60. The company has a debt-to-equity ratio of 4.08, a current ratio of 1.65 and a quick ratio of 1.65. The stock has a 50-day moving average price of $0.97 and a 200 day moving average price of $0.86. The company has a market capitalization of $28.17 million, a PE ratio of -3.35 and a beta of 1.12.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 201.43%.The company had revenue of $0.96 million during the quarter, compared to the consensus estimate of $1.02 million. On average, equities research analysts predict that Dyadic International will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

Several hedge funds have recently bought and sold shares of DYAI. Geode Capital Management LLC grew its holdings in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the period. Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International during the third quarter valued at approximately $190,000. Bank of America Corp DE lifted its holdings in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Dyadic International in the 2nd quarter worth approximately $177,000. Finally, Marathon Capital Management boosted its position in shares of Dyadic International by 142.9% in the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 50,000 shares in the last quarter. Institutional investors own 27.95% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.